NF-κB1基因rs28362491位点多态性对阿托伐他汀疗效的影响

Objective To investigate the effect of polymorphism at the -94ins/del ATTG (rs28362491) site in the promoter region of nuclear transcription factor-κB1 (NF-κB1) on the lipid-lowering and anti-inflammatory efficacy of atorvastatin in patients with coronary heart disease(CHD). Method A total of 180 CHD patients from Jinhua PeoplesHospital in Zhejiang Province from June 2022 to June 2024 were selected as the study subjects and treated with atorvastatin calcium 20 mg·d-1.Detect the genotype of the NF-κB1 gene rs28362491 locus, analyze the levels of blood lipids and inflammatory factors in patients before medication,1and 6 months after medication,and observe the occurrence of adverse reactions during treatment. Results,180 CHD patients underwent genetic testing and were divided into DD type 46, ID type 76, and II type 58. The genotype distribution followed Hardy Weinberg equilibrium (P＞0.05). Before treatment, there was no significant difference in high density lipoprotein cholesterol (HDL-C) levels among the three groups (P＞0.05);The levels of total cholesterol (TC),low density lipoprotein cholesterol(LDL-C), interleukin-6(IL-6), interleukin-8(IL-8),and tumor necrosis factor-α (TNF-α) in DD type were higher than those in ID type and II type (P＜0.05), while there was no significant difference in TC, LDL-C, IL-6, IL-8, and TNF-αlevels between ID type and II type (P＞0.05). After 1 and 6 months of treatment, the levels of TC, LDL-C,IL-6,IL-8, and TNF -α in the three groups of patients decreased significantly compared to before treatment (P＜0.05);At the same time point,the change rates of TC,LDL-C,IL-6,IL-8,and TNF-αlevels in ID and II types were higher than those in DD type (P＜0.05).Within six months of follow-up,there was no significant difference in the incidence of gastrointestinal symptoms, muscle symptoms,liver symptoms, and neurological symptoms among different genotypes (P＞0.05).Conclusion The efficacy of atorvastatin in CHD patients is associated with the rs28362491 polymorphism of the NF-κB1 gene,with II and ID genotypes showing better efficacy than DD genotypes.